Orbit (system of treatment of a retina)

2020: The announcement of Orbit - the system of treatment of a retina without transaction

At the end of September, 2020 the Gyroscope Therapeutics company specializing in gene therapy of a retina provided the system of subretinal delivery of drugs (SDS) Orbit. The technology is intended for treatment of a retina without invasive procedures, such as vitrektomiya at which gel substance from an eye, or a retinotomiya at which the opening in a retina becomes is removed.

The Orbit SDS system provides a microinjection in subretinal space in a back part of an eye. The procedure of a microinjection allows to avoid damage of structure of an eyeball and does not require serious invasive interventions for access to subretinal space.

The system of treatment of a retina without transaction from Gyroscope Therapeutics - Orbit is provided

The company hopes that, combining the medical devices providing low-invasive delivery of drugs, and the innovation gene methods of treatment they will be able to develop new therapeutic strategy. The intended application of the new device is an experimental gene therapy by medicine GT005 on the basis of AAV.

By calculations of developers, GT005 increases an expression of the gene participating in the system of a complement. This gene therapy is intended for treatment of a dry age degeneration of a yellow spot, at people 50 years are more senior than the leading reason of irreversible loss of sight. Meanwhile the dry age degeneration of a yellow spot has no approved treatment.

Researches show that the excess activation of one of parts of the immune system called by the system of a complement is the cornerstone of this disease. Its work is regulated by protein of CFI. Medicine GT005 was developed for recovery of balance in operation of the system of a complement due to increase in production of protein of CFI. It is considered that new therapy will be able to suppress the hyperactive immune answer and inflammation in an eye, thereby having delayed approach of a blindness. Clinical trials of this medicine continue.^[1]

Notes